LUND, Sweden, Nov. 10, 2017 /PRNewswire/ --
The shareholders of Cantargia AB (publ) are summoned to an
extraordinary general meeting on Monday 27
November 2017 at 15.00 CET at Medicon Village, Scheelevägen
2 (conference room Venus, house 301), Lund, Sweden.
Participation and notice
Shareholders who wish to participate in the meeting must:
• be registered in the share register maintained by Euroclear
Sweden AB on Tuesday 21 November
2017, and
• give notice of participation to the company no later than Tuesday
21 November 2017. The notice shall be
made by regular mail to Cantargia AB (publ), Medicon Village,
Scheelevägen 2, SE-223 81 Lund,
Sweden. Notice may also be made by telephone +46 (0)46-27 56
260 or by e-mail info@cantargia.com. The notification shall set
forth name, social security number or company registration number,
number of shares, address, daytime telephone number and, where
applicable, the number of advisors (maximum two) that will
accompany the shareholder at the meeting.
Nominee registered shares
Shareholders, whose shares are nominee registered with a bank or
other nominee, must, in order to be entitled to participate at the
meeting, re-register the shares in their own name. Such
re-registration, which may be temporary, must be made on Tuesday
21 November 2017, which means that a
request from a shareholder for such re-registration must be
submitted to the nominee well in advance of said date.
Proxy etc.
Shareholder represented by a proxy shall issue a power of
attorney for the proxy. If the power of attorney is issued by a
legal entity, a registration certificate or a corresponding
document which indicates the authorized signatories of the legal
entity must be enclosed. The original power of attorney, and any
registration certificate or the equivalent, should be sent to the
company well in advance of the meeting at the address above. A
proxy form is held available at the company's website
www.cantargia.com and will, upon request, be sent by regular mail
to shareholders stating their postal address.
Proposed agenda:
1. Opening of the meeting.
2. Election of chairman of the meeting.
3. Preparation and approval of voting list.
4. Approval of the agenda.
5. Election of one or two persons to verify the minutes.
6. Determination as to whether the meeting has been duly
convened.
7. Appointment and remuneration of new board member.
8. Approval of the board of directors' directed share issue
resolution.
9. Approval of the board of directors' rights issue
resolution.
10. Closure of the meeting.
Election and remuneration of new board member (item
7)
The company's major shareholders propose that Dr. Patricia Delaite is appointed new board member
of the company. It is further proposed that a yearly remuneration
of SEK 80,000 is to be paid to
Patricia Delaite. In addition, in
the event Patricia Delaite performs
additional work for the company outside the scope of the board
assignment, an additional reasonable remuneration may be paid,
following a decision of the board thereon.
Dr. Patricia Delaite, born 1963,
is Medical Doctor and holds an MBA from University of Lausanne. She
is presently Executive Medical director at Incyte Biosciences
International in Geneva and has
previously held leading positions at Ariad Pharmaceutical, Novartis
and Eli Lilly, among others. Furthermore, she has recently
undertaken an executive chief medical officer position in another
company.
Directed share issue (item 8)
The board of directors proposes that the general meeting
approves the board's resolution of 9
November 2017 to increase the company's share capital with
not more than SEK 1,189,200 through
issue of not more than 14,865,000 new shares.
The right to subscribe for the new shares shall, with deviation
from the shareholders' pre-emptive rights, only fall upon a limited
number of investors approached in advance. The subscription price
in the issue shall be SEK 6.80 per
share.
For further details and information on background to and reasons
for the directed share issue, refer to the company's press release
on 9 November 2017.
Rights issue (item 9)
The board of directors proposes that the general meeting
approves the board's resolution of 9
November 2017 to increase the company's share capital with
not more than SEK 1,539,624.32
through issue of not more than 19,245,304 new shares.
The shareholders of the company shall be entitled to subscribe
for the new shares with pre-emptive rights, whereby five existing
shares shall entitle to subscription for three new shares.
Subscription may also be made without pre-emptive rights in
accordance with the terms presented in the complete issue
proposal.
The subscription price in the rights issue shall be SEK 6.80 per share. The record date for the right
to participate in the rights issue shall be 29 November 2017. Subscription for the new shares
shall be made during the period 1 – 15
December 2017. The last day for trading in the Cantargia
share including the right to participate in the rights issue is
27 November 2017.
Cantargia has received subscription and guarantee undertakings
amounting to approximately SEK 131
million. The rights issue is thereby covered by subscription
and guarantee undertakings in its entirety.
For further details and information on background to and reasons
for the rights issue, refer to the company's press release on
9 November 2017.
Miscellaneous
Complete documentation is held available at the company's
offices, Scheelevägen 2 in Lund,
Sweden, and at the company's website (www.cantargia.com).
Copies of the documentation will be sent upon request to
shareholders who provide their postal address. Shareholders are
reminded of their right to require information in accordance with
Chapter 7 Section 32 of the Swedish Companies Act.
Lund, November 2017
Cantargia AB (publ)
The board of directors
For further information, please contact
Göran Forsberg,
CEO
Telephone: +46(0)46-275-62-60
E-mail: goran.forsberg@cantargia.com
This constitutes information that Cantargia is required to
publish under the EU's Market Abuse Regulation and the Swedish
Securities Market Act. The information was submitted for
publication through the above contact person at 13.00 CET on 10
November 2017.
About us
Cantargia AB (publ), reg.no. 556791-6019, is a biotech company
that is developing antibody-based treatments for life threatening
diseases. The original discovery by the research team behind
Cantargia was the overexpression of a specific target molecule,
interleukin 1 receptor accessory protein "IL1RAP", in leukemia stem
cells, later research has also identified IL1RAP in a large number
of other forms of cancer. The lead compound, CAN04 directed against
IL1RAP, will be investigated in the CANFOUR phase I/IIa clinical
trial in with primary focus on non-small lung cancer and pancreatic
cancer. CAN04 has a dual mechanism of action, it blocks IL1RAP
function and stimulates the immune system to eradicate tumor cells.
Cantargias second project is in discovery phase with the goal to
develop an IL1RAP binding antibody optimized for therapy of
autoimmunity and inflammatory diseases.
Cantargia is listed on Nasdaq Stockholm First North (ticker:
CANTA). Sedermera Fondkommission is the company's Certified
Adviser. More information about Cantargia is available at
http://www.cantargia.com.
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/cantargia-ab/r/notice-of-extraordinary-general-meeting-in-cantargia-ab--publ-,c2387869
The following files are available for download:
http://mb.cision.com/Main/7470/2387869/749564.pdf
|
PDF
|